Advertisement
Approximately 4 percent of Americans have a food allergy

~4 Percent of U.S. Population Has Food Allergy, Intolerance

0
Researchers find most common food allergen groups are shellfish, fruit or vegetable, dairy, and peanut
For patients with high-risk vascular disease

Evacetrapib Appears Futile in High-Risk Vascular Disease

0
No reduction in primary end point events, including death from cardiovascular causes, MI, stroke
Anticoagulation for mechanical heart valves during pregnancy is associated with distinct maternal and fetal risks

Distinct Maternal, Fetal Risks for Anticoagulants in Pregnancy

0
VKA, LMWH tied to lowest risk of adverse maternal, fetal outcomes, respectively
The prevalence of arthritis is 31.8 percent in the most rural areas and 20.5 percent in the most urban areas of the United States

CDC: Prevalence of Arthritis 31.8% in Most Rural Areas of U.S.

0
About half of those with arthritis in rural and urban areas have arthritis-attributable activity limitation
Proposed legislation as part of the American Health Care Act

High-Risk Pools May Represent Step Back for U.S. Health Care

0
Higher premiums, deductibles, out-of-pocket costs likely to make high-risk pools unaffordable
For patients with breast cancer receiving endocrine therapy

Daily Texting Effectively Monitors Rx Adherence, Side Effects

0
Most patients with breast cancer taking endocrine therapy report intervention helpful in taking drugs
For patients with food allergy

Quality of Life May Drop for Some During Oral Immunotherapy

0
Patients with better QOL at baseline, might deteriorate after therapy
Suramin

Sleeping Sickness Medication May Help Lessen ASD Symptoms

0
Small study produced positive results with suramin, but more research needed
Ixekizumab (Taltz) appears beneficial in reducing the pain and disability of psoriatic arthritis

Ixekizumab Improves Symptoms in Patients With Psoriatic Arthritis

0
Two-week and four-week ixekizumab dosing regimens improved signs and symptoms
For patients with rheumatoid arthritis

Little Benefit for Etanercept-MTX Before Triple Therapy in RA

0
First-line etanercept-methotrexate would result in 0.15 additional lifetime QALY, at cost of $77,290